» Download Public Reports
About 4 000 reports
- Company report
- May 2013
- 5 pages
- by Corporation
... Involved, even indirectly, with an important therapeutic area that addresses the needs of millions of patients who suffer from respiratory disease is particularly meaningful to all of us at elan." Relvar ...
April 2013
... Health will drive forward public health knowledge, which is a key issue for all governments." The french-german advanced translational drug discovery center is a unique project of public- private ...
May 2013
... That dicobalt edetate only be given when the patient is tending to lose or has lost consciousness. Distamine penicillamine a disease modifying antirheumatic drug (dmard) used for the treatment of rheumatoid ...
April 2013
... Antiretroviral therapy; ci, confidence interval, efv, efavirenz; ftc, emtricitabine; str, single tablet regimen; tdf, tenofovir disoproxil fumarate. Total costs comprised inpatient days, outpatient and dayward ...
April 2013
... Of a pathologic oxygen supply dependency remains contro- versial. Study objective: to evaluate the relationship between oxygen delivery (do2) and oxygen consumption (vo2) during severe sepsis and to compare ...
April 2013
... Nonsurgical polyp removal complete colonic examination age 35 years or older; no history of colorectal cancer, inflammatory bowel disease, or large bowel resection; satisfactory completion of a food ...
April 2013
... And + hydrochlorothiazide tablets 50mg+12,5mg azithromycin azithromycin tablets 250mg,500mg,125mg codelac neo tablets butamirate tablets 50mg new products the following new products are expected to be released ...
April 2013
... Official figures show. Circulatory conditions like heart disease remain the most common cause of death, contributing to a third of the deaths registered. But over the decade, mortality from ...
» Purchase Premium Reports
(From $ 125 - $ 6 995)
About 3 300 reports
- $ 6 995
- Industry report
- February 2013
- by Global Data
PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Protelos (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Forteo (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Reclast (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Odanacatib (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Odanacatib (Osteoporosis) - Forecast and Market Analysis ...
February 2013
$ 6 995
BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
February 2013
$ 6 995
Evista (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Evista (Osteoporosis) - Forecast and Market Analysis to 2022?. ...